King & Spalding successfully defended Novo Nordisk in a federal antitrust suit in New York alleging Novo Nordisk, along with other major insulin manufacturers, conspired to...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here